Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.

Antibodies (Basel) · 2016 · PMC6698862 · PMID 31557987

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A comparison of CTL assay potency of DARTs 30, 20, PF, and 154, which have affinities within three-fold of one another ( Figure 4 C), showed a trend toward higher potency corresponding to more membrane-proximal epitopes.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.